Intranasal delivery of MSCs-Exo relieves AR symptoms
We used an AR mouse model to investigate the role of MSCs-Exo in AR
(Figure 2A). We measured the number of sneezing and nose rubbing motions
during 10 min after the last intranasal administration of OVA. The
results showed that the mice in the AR group sneezed and rubbed more
frequently than those in the control group. Moreover, the numbers of
sneezing and rubbing events were significantly lower in the MSCs-Exo
treatment group compared to the AR group (Figure 2B). In conclusion,
intranasal treatment with MSCs-Exo could notably reduce sneezing and
rubbing frequencies, thus indicating that MSCs-Exo could relieve the
symptoms in AR mice.